ArticleCellular and molecular life sciences : CMLS2014
Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy.
Article in Cellular and molecular life sciences : CMLS, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Mapping the Subtype-Specific PARP1 ADP-Ribosylated Proteome in Breast Cancer Cells.Molecular cancer research : MCR · 2026Article
- The interplay of Ashwagandha with hormonal dynamics and gut microbiota in women with breast cancer: a tri-axial perspective.Journal of natural medicines · 2026Review
- Incorporation of network pharmacology, molecular docking, survival, density functional theory, and experimental studies to explore the potential key targets of formononetin by TERT-mediated anti-cancer effects in MCF-7 breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Mapping the Subtype-Specific PARP1 ADP-ribosylated Proteome in Breast Cancer Cells.bioRxiv : the preprint server for biology · 2025Article
- Forkhead Box Q1 is a novel regulator of autophagy in breast cancer cells.Molecular carcinogenesis · 2023Article
- Structure-Based Multi-Targeted Molecular Docking and Dynamic Simulation of Soybean-Derived Isoflavone Genistin as a Potential Breast Cancer Signaling Proteins Inhibitor.Life (Basel, Switzerland) · 2023Article
- Analysis of Essential Oils Components from Aromatic Plants Using Headspace Repellent Method againstMolecules (Basel, Switzerland) · 2023Article
- Epigenetic Factors as Etiological Agents, Diagnostic Markers, and Therapeutic Targets for Luminal Breast Cancer.Biomedicines · 2022Review
- Overexpression ofCancer management and research · 2020Article
- Distinct Roles for BET Family Members in Estrogen Receptor α Enhancer Function and Gene Regulation in Breast Cancer Cells.Molecular cancer research : MCR · 2019Article
- New dimensions in calix[4]pyrrole: the land of opportunity in supramolecular chemistry.RSC advances · 2019Review
- Cytotoxicity Of Chalcone OfAdvances and applications in bioinformatics and chemistry : AABC · 2019Article
- Oestrogen Inhibits VEGF Expression And Angiogenesis In Triple-Negative Breast Cancer By Activating GPER-1.Journal of Cancer · 2018Article
- Expression ofOncology letters · 2017Article
- Baicalein has protective effects on the 17β-estradiol-induced transformation of breast epithelial cells.Oncotarget · 2017Article
- How interacting pathways are regulated by miRNAs in breast cancer subtypes.BMC bioinformatics · 2016Article
- Transforming growth factor-β signaling pathway cross-talking with ERα signaling pathway on regulating the growth of uterine leiomyoma activated by phenolic environmental estrogens in vitro.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- A calixpyrrole derivative acts as an antagonist to GPER, a G-protein coupled receptor: mechanisms and models.Disease models & mechanisms · 2015Article
- An interspecies conserved motif of the mouse immune system-released activating agent (ISRAA) induces proliferative effects on human cells.Molecular medicine reports · 2014Article
- Krüppel-like factors are effectors of nuclear receptor signaling.General and comparative endocrinology · 2014Review
Corrections and comments
- Retraction · 2014-04-01Euphemisms for Plagiarism · Investigation by Journal/Publisher · Plagiarism of/in Article · Removed · · HTML page overwrite
- Retracted
Authors and funding
7 authors.
Funding
Abstract
Estrogen and estrogen receptors (ERs) are critical regulators of breast epithelial cell proliferation, differentiation, and apoptosis. Compromised signaling vis-à-vis the estrogen receptor is believed to be a major contributing factor in the malignancy of breast cells. Targeting the ER signaling pathway has been a focal point in the development of breast cancer therapy. Although approximately 75 % of breast cancer patients are classified as luminal type (ER(+)), which predicts for response to endocrine-based therapy; however, innate or acquired resistance to endocrine-based drugs remains a serious challenge. The complexity of regulation for estrogen signaling coupled with the crosstalk of other oncogenic signaling pathways is a reason for endocrine therapy resistance. Alternative strategies that target novel molecular mechanisms are necessary to overcome this current and urgent gap in therapy. A thorough analysis of estrogen-signaling regulation is critical. In this review article, we will summarize current insights into the regulation of estrogen signaling as related to breast carcinogenesis and breast cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.